Analysts See $-0.25 EPS for Kadmon Holdings, Inc. (KDMN); ECARE SOLUTIONS (ECSL) Sellers Decreased By 56.25% Their Shorts

April 20, 2018 - By Dolores Ford

Analysts expect Kadmon Holdings, Inc. (NYSE:KDMN) to report $-0.25 EPS on May, 21.They anticipate $0.14 EPS change or 35.90% from last quarter’s $-0.39 EPS. After having $-0.24 EPS previously, Kadmon Holdings, Inc.’s analysts see 4.17% EPS growth. It closed at $4.19 lastly. It is down 15.92% since April 20, 2017 and is uptrending. It has outperformed by 4.37% the S&P500.

ECARE SOLUTIONS INC (OTCMKTS:ECSL) had a decrease of 56.25% in short interest. ECSL’s SI was 4,900 shares in April as released by FINRA. Its down 56.25% from 11,200 shares previously. With 46,400 avg volume, 0 days are for ECARE SOLUTIONS INC (OTCMKTS:ECSL)’s short sellers to cover ECSL’s short positions. It closed at $0.5 lastly. It is down 0.00% since April 20, 2017 and is . It has underperformed by 11.55% the S&P500.

Among 6 analysts covering Kadmon Holdings (NYSE:KDMN), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Kadmon Holdings had 7 analyst reports since August 22, 2016 according to SRatingsIntel. As per Monday, June 26, the company rating was maintained by H.C. Wainwright. Piper Jaffray maintained Kadmon Holdings, Inc. (NYSE:KDMN) rating on Friday, March 24. Piper Jaffray has “Overweight” rating and $23 target. The company was initiated on Monday, August 22 by H.C. Wainwright. Citigroup initiated Kadmon Holdings, Inc. (NYSE:KDMN) rating on Monday, August 22. Citigroup has “Neutral” rating and $12 target. The stock of Kadmon Holdings, Inc. (NYSE:KDMN) has “Outperform” rating given on Monday, August 22 by JMP Securities. The firm has “Hold” rating given on Thursday, March 16 by WBB Securities. Jefferies initiated Kadmon Holdings, Inc. (NYSE:KDMN) on Monday, August 22 with “Buy” rating.

Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics within autoimmune and fibrotic, oncology, and genetic diseases. The company has market cap of $329.55 million. The firm markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including those indicated for the management of rare diseases. It currently has negative earnings. The Company’s lead product candidates include KD025, a rho-associated coiled-coil kinase2 inhibitor, which is in Phase II clinical studies for the treatment of autoimmune, fibrotic, and neurodegenerative diseases; Tesevatinib, an oral tyrosine kinase inhibitor that is in Phase II clinical studies for use in the treatment of non-small cell lung cancer and glioblastoma, as well as for treating autosomal dominant polycystic kidney disease; and KD034 that is used for the treatment of Wilson's disease, a genetic liver disease.

EncounterCare Solutions, Inc. operates as an energy and healthcare firm in the United States. The company has market cap of $24.54 million. It operates through three divisions: Energy, Healthcare Technology, and Healthcare Services. It currently has negative earnings. The Energy division produces and distributes a fuel additive under the EcoFlex 96 brand name.

Kadmon Holdings, Inc. (NYSE:KDMN) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>